

the staff resources and functions to the DIS immediate office; abolished the DIO's Implementation Branch, Infrastructure Engineering Branch, System Operations Branch, Network and Communications Operations Branch, Systems Monitoring and Response Branch, and Systems Monitoring and Response Branch; established the Network Services Branch, Systems Services Branch, and Operations Branch in DIS; realigned staff resources based on their roles and responsibilities; abolished the Delivery Management Support Staff (DMSS) within OTD immediate office; abolished the Application Management Services Staff, Medical Products Branch, OC/CVM/CTP Branch, ORA/CFSAN/CVM Branch, Enterprise Applications Branch, Data Management and Operations Branch within OIMT/OTD/Division of Application Services (DAS); established the Regulatory Operations Branch, Scientific Operations Branch, and Business & Post-Market Branch within DAS; retitled the Office of Data, Analytics, and Research (ODAR), Data Staff to the Analytics Staff; retitled the ODAR Health Informatics Staff to the Informatics Staff; established the Data and Analytics Governance Staff and Data Strategy and Services Staff within ODAR; abolished the Knowledge Management Staff (KMS) within ODAR and realigned the staff resources and functions to the Office of Organizational Excellence, Division of Knowledge & Communications; established the Division of Cybersecurity Capabilities (DCC), Division of Risk & Compliance (DRC), Division of Cybersecurity Operations (DCO), and the Division of Counterintelligence & Insider Threat (DCIT) within the Office of Information Security (OIS); established the Vulnerability Management Branch and Identity Management Branch under OIS/DCC; established the Information System Security Branch and Risk Compliance and Audit Branch under OIS/DRMC; established the CIOCC Operations Branch and Network Security Branch under OIS/DCO; established the Program Staff within the OIS immediate office; realigned OIS staff resources and functions within OIS based on their roles and responsibilities.

The Food and Drug Administration Office of the Commissioner's Office of Digital Transformation is headed by the Chief Information Officer and has been restructured as follows:

Office of Digital Transformation (DCAD)
Office of Information Management and Technology (DCADA)
Enterprise Architecture Staff (DCADA1)
Office of Technology and Delivery (DCADAA)

Division of Infrastructure Services (DCADAAA)
Network Services Branch (DCADAAA1)
Systems Services Branch (DCADAAA2)
Operations Branch (DCADAAA3)
Division of Application Services (DCADAAAB)
Regulatory Operations Branch (DCADAAAB1)
Scientific Operations Branch (DCADAAAB2)
Business and Post-Market Branch (DCADAAAB3)
Division of Engineering (DCADAAC)
Engineering Branch (DCADAAC1)
Implementation Branch (DCADAAC2)
Application Branch (DCADAAC3)
Database & Content Services Branch (DCADAAC4)
Office of Customer Experience (DCADAB)
Division of Collaboration Services (DCADABA)
Division of Service Desk and Support (DCADABB)
Division of Endpoint Management (DCADABC)
Division of End User Services (DCADABD)
Division of Employee Information (DCADABE)
Office of Information Security (DCADB)
Program Staff (DCADB1)
Division of Cybersecurity Capabilities (DCADBA)
Vulnerability Management Branch (DCADBA1)
Identity Management Branch (DCADBA2)
Division of Risk and Compliance (DCADBB)
Information System Security Branch (DCADBB1)
Risk Compliance and Audit Branch (DCADBB2)
Division of Cybersecurity Operations (DCADBC)
CIOCC Operations Branch (DCADBC1)
Network Security Branch (DCADBC2)
Division of Counterintelligence/Insider Threat (DCADBD)
Office of Data, Analytics, and Research (DCADC)
Analytics Staff (DCADC1)
Informatics Staff (DCADC2)
Data and Analytics Governance Staff (DCADC4)
Data Strategy and Services Staff (DCADC5)
Office of Enterprise Portfolio Management (DCADD)
Division of Acquisition Innovation (DCADDA)
Acquisitions Operations Branch (DCADDA1)
Acquisitions Governance Branch (DCADDA2)
IT Asset Management Branch (DCADDA3)

Division of Technology Business Management (DCADDB)
IT Governance Branch (DCADDB1)
Business Intelligence Branch (DCADDB2)
Division of Finance and Budget (DCADDC)
Budget Formulation Branch (DCADDC1)
Budget Execution Branch (DCADDC2)
Office of Organizational Excellence (DCADE)
Talent Strategy Staff (DCADE1)
Executive Services Staff (DCADE2)
Division of People and Culture (DCADEA)
Employee Experience Branch (DCADEA1)
Learning and Development Branch (DCADEA2)
Division of Knowledge and Communications (DCADEB)
Knowledge and Innovation Branch (DCADEB1)
Communications and Outreach Branch (DCADEB2)

II. Delegations of Authority

Pending further delegation, directives, or orders by the Commissioner of Food and Drugs, all delegations and redelegations of authority made to officials and employees of affected organizational components will continue in them or their successors pending further redelegations, provided they are consistent with this reorganization.

III. Electronic Access

This reorganization is reflected in FDA's Staff Manual Guide (SMG). Persons interested in seeing the complete Staff Manual Guide can find it on FDA's website at: <https://www.fda.gov/AboutFDA/ReportsManualsForms/StaffManualGuides/default.htm>.

Authority: 44 U.S.C. 3101.

Xavier Becerra,

Secretary of Health and Human Services.

[FR Doc. 2024-02603 Filed 2-14-24; 8:45 am]

BILLING CODE 4164-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

Agency Information Collection Activities: Submission to OMB for Review and Approval; Public Comment Request; DATA 2000 Waiver Training Payment Program Application for Payment, OMB No. 0906-0061

AGENCY: Health Resources and Services Administration (HRSA), Department of Health and Human Services.

ACTION: Notice.

SUMMARY: In compliance with the Paperwork Reduction Act of 1995, HRSA submitted an Information Collection Request (ICR) to the Office of Management and Budget (OMB) for review and approval. Comments submitted during the first public review of this ICR will be provided to OMB. OMB will accept further comments from the public during the review and approval period. OMB may act on HRSA's ICR only after the 30-day comment period for this notice has closed.

DATES: Comments on this ICR should be received no later than March 18, 2024.

ADDRESSES: Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to www.reginfo.gov/public/do/PRAMain. Find this particular information collection by selecting "Currently under Review—Open for Public Comments" or by using the search function.

FOR FURTHER INFORMATION CONTACT: To request a copy of the clearance requests submitted to OMB for review, email Joella Roland, the HRSA Information Collection Clearance Officer, at paperwork@hrsa.gov or call (301) 443–3983.

SUPPLEMENTARY INFORMATION:

Information Collection Request Title: DATA 2000 Waiver Training Payment Program Application for Payment, OMB No. 0906–0061—Revision.

Abstract: The Substance Use—Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities (SUPPORT) Act (Pub. L. 115–271), section 6083, amended the Social Security Act (subsections 1834(o)(3) and 1833(bb)), authorizing the Secretary of Health and Human Services (Secretary) to pay Federally Qualified Health Centers (FQHC) and Rural Health Clinics (RHC) for the average cost of training for purposes of receiving a DATA 2000 waiver for their physicians and practitioners to furnish opioid use disorder treatment services. The SUPPORT Act made \$6 million available to FQHCs and \$2 million available to RHCs under the DATA 2000

Waiver Training Payment Program. To receive payment, FQHCs and RHCs must submit an application in the manner specified by the Secretary. Authority to administer the DATA 2000 program has been delegated to HRSA. Further information about the program can be found in the link below which provides guidance on the requirements of the DATA 2000 program and how qualified FQHCs and RHCs can apply to the program: <https://help.hrsa.gov/display/public/EHBSKBFG/DATA+2000+Waiver+Training+Payment+Program+FAQs>.

This purpose of this revision is to update the burden estimate for the RHC application process because the funding appropriated for FQHC DATA 2000 payments has been fully expended. Therefore, no new applications for FQHC DATA 2000 payments can be accepted or approved. Only Centers for Medicare & Medicaid Services certified RHCs can apply for payments through the DATA 2000 program, and pursuant to the authorizing statute and subsequent legislation eliminating the DATA 2000 waiver requirement, such RHCs may only receive payments with respect to providers who first received their DATA 2000 Waiver between January 1, 2019, and December 29, 2022.

Applicant entities must provide information identifying the submitting organization and the number of practitioners who have completed training and obtained a DATA 2000 waiver. The form will also require the entity to include information regarding each claimed practitioner's name, practitioner type (e.g., physician, physician assistant, nurse practitioner, certified nurse midwife, clinical nurse specialist, certified registered nurse, or anesthetist), National Provider Identifier number, Drug Enforcement Administration number, state license number, length of training, date the training was completed, date of waiver attainment, and DATA 2000 waiver number. Additionally, the form will require signature of an attestation statement certifying that: (1) each practitioner for which the entity is seeking payment under the application is employed by or working under contract for the applicant health facility; (2) it is the first time the entity is

seeking payment on behalf of the listed practitioner(s); (3) the entity is eligible to seek payment under 42 U.S.C. 1395m(o)(3) or 42 U.S.C. 1395l(bb); (4) each practitioner is furnishing opioid use disorder treatment services; and (5) the statements herein are true, complete, and accurate to the best of the applicant's knowledge.

A 60-day notice published in the **Federal Register** on December 4, 2023, vol. 88, No. 231; pp. 84149–50. There were no public comments.

Need and Proposed Use of the Information: The Substance Use—Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act requires RHCs to submit to the Secretary an application for payment at such time, in such manner, and containing such information as specified by the Secretary in order to receive a payment under section 6083. This form will allow RHCs to apply for such payments based on the average cost of training to obtain DATA 2000 waivers, as determined by the Secretary, for their physicians and practitioners to furnish opioid use disorder treatment services. The form will also provide HRSA with the requisite data to validate qualifying DATA 2000 waiver possessions for the purpose of ensuring accurate payments to RHCs.

Likely Respondents: Only Centers for Medicare & Medicaid Services certified RHCs are eligible to apply.

Burden Statement: Burden in this context means the time expended by persons to generate, maintain, retain, disclose, or provide the information requested. This includes the time needed to review instructions; to develop, acquire, install, and utilize technology and systems for the purpose of collecting, validating, and verifying information, processing and maintaining information, and disclosing and providing information; to train personnel and to be able to respond to a collection of information; to search data sources; to complete and review the collection of information; and to transmit or otherwise disclose the information. The total annual burden hours estimated for this ICR are summarized in the table below.

TOTAL ESTIMATED ANNUALIZED BURDEN HOURS

Form name	Number of respondents	Number of responses per respondent	Total responses	Average burden per response (in hours)	Total burden hours
DATA 2000 Waiver Training Payment Program Application for Payment	300	1	300	0.5	150.0

TOTAL ESTIMATED ANNUALIZED BURDEN HOURS—Continued

Form name	Number of respondents	Number of responses per respondent	Total responses	Average burden per response (in hours)	Total burden hours
Total	300	1	300	150.0

Maria G. Button,

Director, Executive Secretariat.

[FR Doc. 2024–03092 Filed 2–14–24; 8:45 am]

BILLING CODE 4165–15–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Special Emphasis Panel: Cardiovascular Differentiation and Development.

Date: March 6, 2024.

Time: 9:30 a.m. to 7:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Sara Ahlgren, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, RM 4136, Bethesda, MD 20892, 301–435–0904, sara.ahlgren@nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; RFA: RM–23–015 Pilot Projects Enhancing Utility and Usage of Common Fund Data Sets Review.

Date: March 13, 2024.

Time: 10:00 a.m. to 7:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Katherine M. Malinda, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4140,

MSC 7814, Bethesda, MD 20892, (301) 435–0912, malindakm@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; RFA Panel: Animal and Biological Material Resource Centers and Resource-Related Research Projects.

Date: March 13, 2024.

Time: 10:00 a.m. to 8:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Michael L. Bloom, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6187, MSC 7804, Bethesda, MD 20892, 301–451–0132, bloommm2@mail.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Cell and Developmental Biology of Eye.

Date: March 13, 2024.

Time: 2:00 p.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Rass M. Shaiyiq, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 2182, MSC 7818, Bethesda, MD 20892, (301) 435–2359, shaiyiq@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Small Business: Biomedical Sensing, Measurement and Instrumentation.

Date: March 14–15, 2024.

Time: 8:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Hilton Washington/Rockville, 1750 Rockville Pike, Rockville, MD 20852.

Contact Person: Steven Anthony Ripp, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 594–3010, steven.ripp@nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Small Business: Neuroscience Assays, Diagnostics, Instrumentation, and Interventions.

Date: March 14–15, 2024.

Time: 8:30 a.m. to 8:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Aurea D. De Sousa, Ph.D., Scientific Review Officer, Center for

Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5186, Bethesda, MD 20892, (301) 827–6829, aurea.desousa@nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Small Business: Biological Chemistry, Biophysics, and Assay Development.

Date: March 14–15, 2024.

Time: 9:00 a.m. to 7:30 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: John Harold Laity, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 402–8254, laityjh@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Small Business: Health Services and Systems.

Date: March 14–15, 2024.

Time: 9:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Michael J. McQuestion, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3114, Bethesda, MD 20892, 301–480–1276, mike.mcquestion@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: February 12, 2024.

David W. Freeman,

Supervisory Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2024–03197 Filed 2–14–24; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.